A case of osteoclastoma (myeloid sarcoma, benign giant cell tumour) with pulmonary metastasis

Finch, Ernest; Gleave, HumphreyH.

doi:10.1002/path.1700290408

Cited by 31 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finch and Gleave [10] reported pulmonary metastasis of benign GCTB for the first time in 1926. Initial pulmonary metastases are rare, and most appear after the operation of the primary tumor.…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Yang

Huang

Niu

et al. 2017

Journal of Bone Oncology

View full text Add to dashboard Cite

Pulmonary metastasis of benign giant cell tumor of bone is very rare, and its biological behavior is difficult to predict. In the present study, we analyzed the clinical characteristics of and related risk factors for pulmonary metastasis from this tumor. Forty-six patients with lung metastasis were analyzed. In total, 60.9% of the primary tumors were located around the knee joint. The Campanacci stage of all tumors was stage 3. Surgery of the primary tumor included curettage in 37 patients, resection in 8, and amputation in 1. Local recurrence after the primary surgery occurred in 34 patients. The recurrence rate, Campanacci stage, and surgical method were significant risk factors for lung metastasis. The median postoperative metastasis times in the lower limbs, upper limbs, and axial skeleton were 20.1, 7.9, and 1.4 months, respectively (p=0.010). The median metastasis times in patients with and without recurrence were 13.7 and 43.2 months, respectively (p=0.018). Eighteen patients had unilateral metastasis and 28 had bilateral metastasis. Most lesions (n=38) were located in the peripheral lung. Nineteen patients received treatment, and 12 of them underwent tumor resection. The 5-year overall survival rate was 94.4%. This study showed that local recurrence, a high Campanacci stage, and curettage were possible high-risk factors for pulmonary metastasis. The primary lesion site and local recurrence may be related to the metastasis time. The survival rate of patients with pulmonary metastasis was high.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Yang

Huang

Niu

et al. 2017

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…However, few GCTBs (1%-6%) transform into malignancies, particularly after radiotherapy or multiple local surgeries and recurrences [ 3 – 5 ]. Finch and Gleave first described pulmonary metastasis in benign GCTB, prior to which metastasis was only associated with malignant GCTBs [ 6 ]. Distal metastasis of benign GCTBs occurs in various sites, including the lung, liver and skin, and pulmonary metastases are most commonly observed [ 7 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a prognostic index to predict pulmonary metastasis of giant cell tumor of bone

et al. 2017

View full text Add to dashboard Cite

PurposeGiant cell tumor of bone (GCTB) is an intermittent tumor with a low probability of pulmonary metastasis. Our aim was to investigate the risk factors and establish a nomogram predictive model for GCTB pulmonary metastasis.MethodsWe retrospectively evaluated GCTB patients at our center from 1991 to 2014. The cohort was randomized into training and validation sets. Univariate and multivariate analyses were used to evaluate the risk factors of pulmonary metastasis. A nomogram was established. Internal validation was achieved based on ROC curve and C-index values in the validation set. Decision curve analysis was performed to assess the clinical performance of the nomogram.Results417 patients were studied, including benign and malignant GCTBs. The average follow up was 79 months. Pulmonary metastases were observed in 27 cases. Four independent risk factors were identified: malignancy, tumor bearing time, times of recurrence and tumor size. A nomogram was developed to predict pulmonary metastasis with C-index values of 0.857 and 0.785 in the training and validation groups. In the decision curve analysis, patients could benefit from the nomogram, which differentiates patients at high risk for pulmonary metastasis and avoids unnecessary examination. According to the nomogram, patients with final risks of more than 0.06 should be scheduled for further chest scans.ConclusionMalignancy, tumor bearing time, times of recurrence and tumor size were independent risk factors for pulmonary metastasis in GCTB patients. The nomogram can accurately predict the risk of pulmonary metastasis and help doctors to make clinical decisions for further chest examinations.

show abstract

“…3 Hitherto, they had been considered as a type of sarcoma. Today, the concept of benign metastases is well recognised and their occurrence comprises 2% of all metastases.…”

Section: Discussionmentioning

confidence: 99%

Multiple skeletal metastases from a giant cell tumour of the distal fibula with fatal outcome

Leichtle

Gärtner

et al. 2006

The Journal of Bone and Joint Surgery. British volume

View full text Add to dashboard Cite

A giant cell tumour is a primary lesion of bone of intermediate severity. Its histogenesis is unclear. In a few cases pulmonary metastases have been described. Multiple skeletal metastases in the absence of sarcomatous change have been observed. We present a case report of a 25-year-old woman with a recurrent giant cell tumour of the distal fibula. After a second recurrence and six years after the initial diagnosis, she rapidly developed multiple bony metastases. The outcome was fatal.

show abstract

A case of osteoclastoma (myeloid sarcoma, benign giant cell tumour) with pulmonary metastasis

Cited by 31 publications

References 5 publications

Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Development and validation of a prognostic index to predict pulmonary metastasis of giant cell tumor of bone

Multiple skeletal metastases from a giant cell tumour of the distal fibula with fatal outcome

Contact Info

Product

Resources

About